Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: A randomised, placebo-controlled, phase III trial

被引:100
作者
Portman, D. [1 ]
Palacios, S. [2 ]
Nappi, R. E. [3 ]
Mueck, A. O. [4 ]
机构
[1] Columbus Ctr Womens Hlth Res, Columbus, OH 43213 USA
[2] Inst Palacios Salud & Med Mujer, Madrid 28009, Spain
[3] Univ Pavia, IRCCS S Matteo Fdn, Res Ctr Reprod Med Gynecol Endocrinol & Menopause, I-27100 Pavia, Italy
[4] Univ Womens Hosp, Tubingen, Germany
关键词
Vaginal dryness; Ospemifene; Vulvar and vaginal atrophy; Postmenopausal; Dyspareunia; MANAGEMENT; SAFETY; EFFICACY; THERAPY; HEALTH; IMPACT; VIEWS;
D O I
10.1016/j.maturitas.2014.02.015
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Objective: To evaluate the efficacy and safety of ospemifene, a novel selective oestrogen receptor modulator, in the treatment of vaginal dryness in postmenopausal women with vulvovaginal atrophy (VVA). Study design: A 12 week, multicentre, randomised, double-blind, parallel-group phase III study of women (40-80 years) with VVA and self-reported vaginal dryness as their most bothersome symptom. Main outcome measures: The co-primary efficacy endpoints were the change from baseline to Week 12 in (1) percentage of parabasal cells in the maturation index (MI), (2) percentage of superficial cells in the MI, (3) vaginal pH, and (4) severity of vaginal dryness. Safety assessments included physical examination, cervical Papanicolaou test and clinical laboratory analyses. Endometrial thickness and histology was also assessed. Results: A total of 314 women were randomised to once-daily ospemifene 60 mg/day (n = 160) or placebo (n = 154). Significant improvements in the percentages of parabasal and superficial cells in the MI and vaginal pH were observed with ospemifene compared with placebo (p<0.001 for all parameters). The mean change from baseline in severity score of vaginal dryness reported by women receiving ospemifene compared with those receiving placebo approached statistical significance (p = 0.080). Improvements in each of the four co-primary endpoints with ospemifene were statistically significant compared to placebo in the per protocol population. The majority of treatment-emergent adverse events were considered mild to moderate in severity. Conclusions: Once-daily oral ospemifene 60 mg was effective for the treatment of VVA in postmenopausal women with vaginal dryness. (C) 2014 The Authors. Published by Elsevier Ireland Ltd.
引用
收藏
页码:91 / 98
页数:8
相关论文
共 33 条
[1]   Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview [J].
Al-Baghdadi, O. ;
Ewies, A. A. A. .
CLIMACTERIC, 2009, 12 (02) :91-105
[2]  
[Anonymous], 2013, FDA APPR OSPH POSTM
[3]  
Bachmann GA, 2000, AM FAM PHYSICIAN, V61, P3090
[4]   Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally [J].
Bachmann, Gloria ;
Bouchard, Celine ;
Hoppe, Diana ;
Ranganath, Radhika ;
Altomare, Corrado ;
Vieweg, Alberta ;
Graepel, Jay ;
Helzner, Eileen .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2009, 16 (04) :719-727
[5]   Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study [J].
Bachmann, Gloria A. ;
Komi, Janne O. .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2010, 17 (03) :480-486
[6]   Behavior and Symptom Change Among Women Treated with Placebo for Sexual Dysfunction [J].
Bradford, Andrea ;
Meston, Cindy M. .
JOURNAL OF SEXUAL MEDICINE, 2011, 8 (01) :191-201
[7]   Measuring symptom relief in studies of vaginal and vulvar atrophy: the most bothersome symptom approach [J].
Ettinger, Bruce ;
Hait, Howard ;
Reape, Kathleen Z. ;
Shu, Haibin .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2008, 15 (05) :885-889
[8]   Biological, clinical, and ethical advances of placebo effects [J].
Finniss, Damien G. ;
Kaptchuk, Ted J. ;
Miller, Franklin ;
Benedetti, Fabrizio .
LANCET, 2010, 375 (9715) :686-695
[9]   Practical aspects in the management of vaginal atrophy and sexual dysfunction in perimenopausal and postmenopausal women [J].
Goldstein, I ;
Alexander, JL .
JOURNAL OF SEXUAL MEDICINE, 2005, 2 :154-165
[10]   Recognizing and Treating Urogenital Atrophy in Postmenopausal Women [J].
Goldstein, Irwin .
JOURNAL OF WOMENS HEALTH, 2010, 19 (03) :425-432